Transdermal [Regulatives / Guidelines]

posted by Kelen – Brazil, 2020-06-29 20:51 (1386 d 15:31 ago) – Posting: # 21605
Views: 1,149

Hi everyone,
In Brazil we are implementing the guideline about generic transdermal products and I have some doubts about the EMA Guideline.

(1) About the sensitisation and irritation test, is it dependent on how the medication is used or should it always be done as described in the guide, a patch every day even if the patch is to be used for more than 24 hours?

(2) Is a multiple dose study necessary if accumulation is observed or is there any other condition that would dispense this study with transdermal patches?

I would appreciate a lot any kind of help.
Thanks in advance!

Kelen

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,649 registered users;
46 visitors (0 registered, 46 guests [including 6 identified bots]).
Forum time: 12:23 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5